Tools

LEADER 02549nam 2200553 i 4500

001 on1572064989;

005 20260206111001.0;

006 m o d f ;

007 cr |||||||||||;

008 260206s2026 dcuab ob f000 0 eng c;

035 a| (Sirsi) o1572064989;

035 a| (OCoLC)1572064989;

042 a| pcc;

043 a| n-us---;

049 a| ERE#;

074 a| 0546-D (online);

086 0 a| GA 1.13:GAO-26-107691;

088 a| GAO-26-107691;

110 1 a| United States.b| Government Accountability Office,e| author.;

245 10 a| Rare diseases: funding for rare neurodegenerative disease research and access to ALS investigational drugs :b| report to congressional committees.;

246 30 a| Funding for rare neurodegenerative disease research and access to ALS investigational drugs, report to congressional committees;

246 17 a| Rare Diseases Research;

264 1 a| Washington, DC :b| U.S. Government Accountability Office,c| 2026.;

300 a| 1 online resource (ii, 54 pages) :b| color illustrations, maps;

336 a| textb| txt2| rdacontent;

337 a| computerb| c2| rdamedia;

338 a| online resourceb| cr2| rdacarrier;

500 a| "February 2026.";

500 a| "GAO-26-107691.";

500 a| This is a publication issued by the United States federal government or produced with federal funds.;

500 a| In scope of the U.S. Government Publishing Office Cataloging and Indexing Program (C&I) and Federal Depository Library Program (FDLP).;

504 a| Includes bibliographical references (pages 52-53).;

588 a| Description based on online resource; title from PDF cover (GAO, viewed February 5, 2026).;

610 20 a| National Institutes of Health (U.S.)x| Research grants.;

610 10 a| United States.b| Food and Drug Administrationx| Research grants.;

650 0 a| Nervous systemx| Degenerationz| United States.;

650 0 a| Amyotrophic lateral sclerosisx| Treatmentz| United States.;

650 0 a| Clinical trialsz| United States.;

856 40 u| https://purl.fdlp.gov/GPO/gpo2525137| 0;

856 4 z| Address at time of PURL creationu| https://www.gao.gov/assets/gao-26-107691.pdf;

949 a| Click on web addressw| asish| joyner94o| jjlm;

994 a| C0b| GPO;

955 a| bc106 20260206b| 20260206;

922 a| UNREPORTEDPUBSSTAFFb| 20260206;

922 a| BIBCONEWb| 20260206;

596 a| 1;

998 a| 6714408;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6714408-1001l| JNETm| JOYNERr| Ys| Yt| JNE1DOu| 3/27/2026x| EDOCUMENTz| JERESOURCEo| .STAFF. jjlm;

Rare diseases: funding for rare neurodegenerative disease research and access to ALS investigational drugs : report to congressional committees.

Author/creator	United States
Format	Electronic
Publication	Washington, DC : U.S. Government Accountability Office, 2026.
Description	1 online resource (ii, 54 pages) : color illustrations, maps
Supplemental Content	https://purl.fdlp.gov/GPO/gpo252513
Supplemental Content	Address at time of PURL creation
Subjects	National Institutes of Health (U.S.)--Research grants. United States. Food and Drug Administration--Research grants. Nervous system--Degeneration. --United States. Amyotrophic lateral sclerosis--Treatment. --United States. Clinical trials--United States.

Portion of title	Funding for rare neurodegenerative disease research and access to ALS investigational drugs, report to congressional committees
Running title	Rare Diseases Research
General note	"February 2026."
General note	"GAO-26-107691."
General note	This is a publication issued by the United States federal government or produced with federal funds.
General note	In scope of the U.S. Government Publishing Office Cataloging and Indexing Program (C&I) and Federal Depository Library Program (FDLP).
Bibliography note	Includes bibliographical references (pages 52-53).
Source of description	Description based on online resource; title from PDF cover (GAO, viewed February 5, 2026).
Technical rpt number	GAO-26-107691
GPO item number	0546-D (online)
Govt. docs number	GA 1.13:GAO-26-107691

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Online Content https://purl.fdlp.gov/GPO/gpo252513 Address at time of PURL creation	✔ Available

Rare diseases: funding for rare neurodegenerative disease research and access to ALS investigational drugs : report to congressional committees.

Click here for more information about this title

Availability